Biosimilars | Access & Reimbursement | US/EU | 2024
*Key drugs covered: *Admelog / Insulin Lispro Sanofi, Aranesp, Avastin, Basaglar / Abasaglar, Enbrel, Herceptin, Herzuma, Hulio, Humalog, Humira,Inflectra, Kanjinti, Neulasta, Neupogen, Nivestim / Nivestym, Nyvepria, Remicade, Remsima, Rituxan / MabThera, Semglee, Trazimera, Truxima, Udenyca,Zarzio / Zarxio, Ziextenzo
Related Market Assessment Reports
Report
Uterine Fibroids – Current Treatment – Treatment Algorithms: Claims Data Analysis – Uterine Fibroids (US)
Treatment for uterine fibroids includes pharmacological approaches and surgical procedures. NSAIDs help alleviate the pain but do not reduce the fibroids’ size. Progestins (e.g., norethindrone,…
Report
Irritable Bowel Syndrome – Current Treatment – Treatment Algorithms: Claims Data Analysis – IBS-Constipation (Including IBS Without Diarrhea) (US)
Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder characterized by alterations in motility, stool consistency and frequency, and urgency. It is classified into three subtypes:…
Report
Kidney Transplant – Current Treatment – Treatment Algorithms: Claims Data Analysis – Kidney Transplant (US)
Each year in the United States, thousands of patients with end-stage renal disease undergo a kidney transplant. To prevent rejection and maintain the new kidney’s functionality, patients must…
